As of August 2019, the Danish pharmaceutical company Novo Nordisk controlled about 77 percent of the premix insulin market in Greater China. Overall, its leadership in the Chinese insulin market dropped slightly compared to the previous year, whereas local insulin manufacturers held around 33 percent of the market. Founded in 1923, the firm specializes in producing diabetes medications, which accounted for 80 percent of its annual sales revenue in 2019.
…. more: Statista.com (Quelle/Source)